Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotechnology Value Fund, L.P. -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (695)	6/9/1999 4:47:00 PM
From: scaram(o)uche	Read Replies (2) \| Respond to of 4974

Pfizer seems to have a few problems with potential toxicities. Here's the latest......... biz.yahoo.com I think I know why they have so many problems. Companies take on personalities based on the type of person that they retain long-term. If you watch long enough, you can "feel" the culture from outside. It's unrelated, but perhaps they should increase their scientist:attorney ratio? Celexa sure is looking like an attractive alternative to Prozac, for those patients who might have reimbursement issues.

To: scaram(o)uche who wrote (695)	6/9/1999 5:05:00 PM
From: scaram(o)uche	Read Replies (3) \| Respond to of 4974

Question about cox-2 inhibitors...... I don't understand. I never looked at the question in particular detail, as it seemed pretty simple. I may just be missing something that's very obvious....... They were supposed to be better than aspirin et al. because they didn't target the enzyme that protects the gut. But, aren't they being approved without the desired gut labeling? How much do they cost? Excedrine is a miracle medicine for me, and I worry more about the acetominophen component than the aspirin.